L6H21 | LPS-TLR4/MD-2 Inhibitor

MedKoo Cat#: 565158 | Name: L6H21

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L6H21 is an inhibitor of the interaction and signaling transduction of LPS-TLR4/MD-2 (myeloid differentiation 2).

Chemical Structure

L6H21

CAS#24533-47-9

Theoretical Analysis

MedKoo Cat#: 565158

Name: L6H21

CAS#: 24533-47-9

Chemical Formula: C18H18O4

Exact Mass: 298.1205

Molecular Weight: 298.34

Elemental Analysis: C, 72.47; H, 6.08; O, 21.45

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 285.00	2 Weeks
25mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L6H21; L6H 21; L6H-21;

IUPAC/Chemical Name

(E)-2,3-dimethoxy-4'-methoxychalcone

InChi Key

IECVLMVZGCYCSZ-FMIVXFBMSA-N

InChi Code

InChI=1S/C18H18O4/c1-20-15-10-7-13(8-11-15)16(19)12-9-14-5-4-6-17(21-2)18(14)22-3/h4-12H,1-3H3/b12-9+

SMILES Code

O=C(C1=CC=C(OC)C=C1)/C=C/C2=CC=CC(OC)=C2OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 298.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yu FZ, Wen X, Ding WL, Zhu JY, Du SH, Shen QF, Ni X, Wang J. L6H21 prolonged rats survival after limb allotransplantation by inhibiting acute rejection. Eur Rev Med Pharmacol Sci. 2017 Apr;21(8):1891-1903. PubMed PMID: 28485788. 2: Wang Y, Shan X, Chen G, Jiang L, Wang Z, Fang Q, Liu X, Wang J, Zhang Y, Wu W, Liang G. MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol. 2015 Sep;172(17):4391-405. doi: 10.1111/bph.13221. Epub 2015 Jul 21. PubMed PMID: 26076332; PubMed Central PMCID: PMC4556476. 3: Hong GL, Yang ZN, He YY, Tan JP, Liangm A, Zhao GJ, Lu ZQ. [Mono-carbonyl analogues of curcumin prevents paraquat-induced apoptosis in HK-2 cell line by inhibiting oxidative damage and inflammation]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2017 Sep 20;35(9):641-647. doi: 10.3760/cma.j.issn.1001-9391.2017.09.001. Chinese. PubMed PMID: 29294513. 4: Chen X, Yu W, Li W, Zhang H, Huang W, Wang J, Zhu W, Fang Q, Chen C, Li X, Liang G. An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by attenuating inflammation. Toxicol Appl Pharmacol. 2018 Jan 1;338:43-53. doi: 10.1016/j.taap.2017.11.003. Epub 2017 Nov 8. PubMed PMID: 29128402. 5: Zhang Y, Wu B, Zhang H, Ge X, Ying S, Hu M, Li W, Huang Y, Wang L, Chen C, Shan X, Liang G. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease. J Cell Mol Med. 2018 Feb;22(2):936-947. doi: 10.1111/jcmm.13395. Epub 2017 Oct 27. PubMed PMID: 29077272; PubMed Central PMCID: PMC5783870. 6: Fang Q, Wang J, Zhang Y, Wang L, Li W, Han J, Huang W, Liang G, Wang Y. Inhibition of myeloid differentiation factor-2 attenuates obesity-induced cardiomyopathy and fibrosis. Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):252-262. doi: 10.1016/j.bbadis.2017.09.026. Epub 2017 Sep 29. PubMed PMID: 28965884. 7: Fang Q, Wang L, Yang D, Chen X, Shan X, Zhang Y, Lum H, Wang J, Zhong P, Liang G, Wang Y. Blockade of myeloid differentiation protein 2 prevents obesity-induced inflammation and nephropathy. J Cell Mol Med. 2017 Dec;21(12):3776-3786. doi: 10.1111/jcmm.13287. Epub 2017 Aug 2. PubMed PMID: 28767204; PubMed Central PMCID: PMC5706499. 8: Xu Z, Li W, Han J, Zou C, Huang W, Yu W, Shan X, Lum H, Li X, Liang G. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep. 2017 Mar 21;7:44911. doi: 10.1038/srep44911. PubMed PMID: 28322341; PubMed Central PMCID: PMC5359637. 9: Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, Pan Y, Xu Z, Bai B, Huang W, Liang G. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway. Basic Res Cardiol. 2017 Jan;112(1):9. doi: 10.1007/s00395-016-0599-5. Epub 2016 Dec 24. PubMed PMID: 28013347. 10: Fang Q, Zhao L, Wang Y, Zhang Y, Li Z, Pan Y, Kanchana K, Wang J, Tong C, Li D, Liang G. A novel chalcone derivative attenuates the diabetes-induced renal injury via inhibition of high glucose-mediated inflammatory response and macrophage infiltration. Toxicol Appl Pharmacol. 2015 Jan 15;282(2):129-38. doi: 10.1016/j.taap.2014.10.021. Epub 2014 Nov 8. PubMed PMID: 25447405.